OrisDX develops a non-invasive salivary diagnostic test that utilizes next-generation sequencing and proprietary algorithms to detect genetic biomarkers associated with oral cavity pre-malignancies and cancers. This technology addresses the issue of late-stage detection in over 60% of head and neck cancer cases by enabling rapid and accurate diagnosis through saliva samples.
Funding
$930K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GSFounders
Product
Problem
Late-stage detection occurs in over 60% of head and neck cancer cases, contributing to poorer patient outcomes. Current diagnostic methods can be invasive or uncomfortable, potentially delaying necessary screenings. The increasing incidence of late-stage oral cancer detection highlights the need for more accessible and accurate diagnostic tools.
Solution
OrisDX has developed a non-invasive salivary diagnostic test for the early detection of oral cavity pre-malignancies and cancers. The test utilizes next-generation sequencing and proprietary algorithms to analyze genetic biomarkers present in saliva samples. This approach enables rapid and accurate diagnosis, addressing the challenge of late-stage detection. By providing a non-invasive and easily accessible method, OrisDX aims to improve early detection rates and ultimately enhance patient outcomes in head and neck cancer.
Target Audience
The primary target audience includes oncologists, dentists, and other healthcare professionals involved in the diagnosis and treatment of head and neck cancers, as well as individuals at high risk for developing these cancers.
Features
- Non-invasive saliva sample collection for patient comfort and ease of use
- Next-generation sequencing technology for comprehensive genetic biomarker analysis
- Proprietary algorithms for accurate detection of oral cancer and pre-cancerous lesions
- High detection rate, identifying over 93% of oral cancers
- Rapid results turnaround time for timely clinical decision-making
- Multiomic platform integrating various molecular data for enhanced diagnostic precision